Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy

With the recent FDA approval of Kite Pharmaceuticals CD19 targeting Chimeric Antigen Receptor (CAR) T-cell therapy (KTE-C19, Axicabtagene ciloleucel, Yescarta, Kite Pharma—a subsidiary of Gilead, F...